|
1
|
Ohgaki H and Kleihues P: Population-based
studies on incidence, survival rates and genetic alterations in
astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol.
64:479–489. 2005.PubMed/NCBI
|
|
2
|
Smoll NR, Gautschi OP, Schatlo B, Schaller
K and Weber DC: Relative survival of patients with supratentorial
low-grade gliomas. Neuro Oncol. 14:1062–1069. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Spinelli GP, Miele E, Lo Russo G, Miscusi
M, Codacci-Pisanelli G, Petrozza V, Papa A, Frati L, Della Rocca C,
Gulino A and Tomao S: Chemotherapy and target therapy in the
management of adult high-grade gliomas. Curr Cancer Drug Targets.
12:1016–1031. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wang Y and Jiang T: Understanding high
grade glioma: Molecular mechanism, therapy and comprehensive
management. Cancer Lett. 331:139–146. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Newlands ES, Stevens MF, Wedge SR,
Wheelhouse RT and Brock C: Temozolomide: A review of its discovery,
chemical properties, pre-clinical development and clinical trials.
Cancer Treat Rev. 23:35–61. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Stupp R, Hegi ME, Mason WP, van den Bent
MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B,
Belanger K, et al: Effects of radiotherapy with concomitant and
adjuvant temozolomide versus radiotherapy alone on survival in
glioblastoma in a randomised phase III study: 5-year analysis of
the EORTC-NCIC trial. Lancet Oncol. 10:459–466. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cao Z, Liu LZ, Dixon DA, Zheng JZ,
Chandran B and Jiang BH: Insulin-like growth factor-I induces
cyclooxygenase-2 expression via PI3K, MAPK and PKC signaling
pathways in human ovarian cancer cells. Cell Signal. 19:1542–1553.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Weroha SJ and Haluska P: The insulin-like
growth factor system in cancer. Endocrinol Metab Clin North Am.
41:335–350. vi2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jenkins PJ, Frajese V, Jones AM,
Camacho-Hubner C, Lowe DG, Fairclough PD, Chew SL, Grossman AB,
Monson JP, Besser GM, et al: Insulin-like growth factor I and the
development of colorectal neoplasia in acromegaly. J Clin
Endocrinol Metab. 85:3218–3221. 2000.PubMed/NCBI
|
|
10
|
Lukanova A, Lundin E, Toniolo P, Micheli
A, Akhmedkhanov A, Rinaldi S, Muti P, Lenner P, Biessy C, Krogh V,
et al: Circulating levels of insulin-like growth factor-I and risk
of ovarian cancer. Int J Cancer. 101:549–554. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Roddam AW, Allen NE, Appleby P, Key TJ,
Ferrucci L, Carter HB, Metter EJ, Chen C, Weiss NS, Fitzpatrick A,
et al: Insulin-like growth factors, their binding proteins and
prostate cancer risk: Analysis of individual patient data from 12
prospective studies. Ann Intern Med. 149:461–471. W83–W88. 2008.
View Article : Google Scholar
|
|
12
|
Endogenous Hormones and Breast Cancer
Collaborative Group; Key TJ, Appleby PN, Reeves GK and Roddam AW:
Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3)
and breast cancer risk: Pooled individual data analysis of 17
prospective studies. Lancet Oncol. 11:530–542. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hirano H, Lopes MB, Laws ER Jr, Asakura T,
Goto M, Carpenter JE, Karns LR and VandenBerg SR: Insulin-like
growth factor-1 content and pattern of expression correlates with
histopathologic grade in diffusely infiltrating astrocytomas. Neuro
Oncol. 1:109–119. 1999.
|
|
14
|
Resnicoff M, Sell C, Rubini M, Coppola D,
Ambrose D, Baserga R and Rubin R: Rat glioblastoma cells expressing
an antisense RNA to the insulin-like growth factor-1 (IGF-1)
receptor are nontumorigenic and induce regression of wild-type
tumors. Cancer Res. 54:2218–2222. 1994.PubMed/NCBI
|
|
15
|
Yin S, Girnita A, Strömberg T, Khan Z,
Andersson S, Zheng H, Ericsson C, Axelson M, Nistér M, Larsson O,
et al: Targeting the insulin-like growth factor-1 receptor by
picropodophyllin as a treatment option for glioblastoma. Neuro
Oncol. 12:19–27. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gariboldi MB, Ravizza R and Monti E: The
IGFR1 inhibitor NVP-AEW541 disrupts a pro-survival and
pro-angiogenic IGF-STAT3-HIF1 pathway in human glioblastoma cells.
Biochem Pharmacol. 80:455–462. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Schlenska-Lange A, Knüpfer H, Lange TJ,
Kiess W and Knüpfer M: Cell proliferation and migration in
glioblastoma multiforme cell lines are influenced by insulin-like
growth factor I in vitro. Anticancer Res. 28:1055–1060.
2008.PubMed/NCBI
|
|
18
|
Sabbatini P, Korenchuk S, Rowand JL, Groy
A, Liu Q, Leperi D, Atkins C, Dumble M, Yang J, Anderson K, et al:
GSK1838705A inhibits the insulin-like growth factor-1 receptor and
anaplastic lymphoma kinase and shows antitumor activity in
experimental models of human cancers. Mol Cancer Ther. 8:2811–2820.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bao NR, Lu M, Bin FW, Chang ZY, Meng J,
Zhou LW, Guo T and Zhao JN: Systematic screen with kinases
inhibitors reveals kinases play distinct roles in growth of
osteoprogenitor cells. Int J Clin Exp Pathol. 6:2082–2091.
2013.PubMed/NCBI
|
|
20
|
Anisimov VN and Bartke A: The key role of
growth hormone-insulin-IGF-1 signaling in aging and cancer. Crit
Rev Oncol Hematol. 87:201–223. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Nicoletti I, Migliorati G, Pagliacci MC,
Grignani F and Riccardi C: A rapid and simple method for measuring
thymocyte apoptosis by propidium iodide staining and flow
cytometry. J Immunol Methods. 139:271–279. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Trojan J, Cloix JF, Ardourel MY, Chatel M
and Anthony DD: Insulin-like growth factor type I biology and
targeting in malignant gliomas. Neuroscience. 145:795–811. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Freeman DJ, Li AG, Wei G, Li HH, Kertesz
N, Lesche R, Whale AD, Martinez-Diaz H, Rozengurt N, Cardiff RD, et
al: PTEN tumor suppressor regulates p53 protein levels and activity
through phosphatase-dependent and -independent mechanisms. Cancer
Cell. 3:117–130. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Choe G, Horvath S, Cloughesy TF, Crosby K,
Seligson D, Palotie A, Inge L, Smith BL, Sawyers CL and Mischel PS:
Analysis of the phosphatidylinositol 3′-kinase signaling pathway in
glioblastoma patients in vivo. Cancer Res. 63:2742–2746.
2003.PubMed/NCBI
|
|
25
|
Ishii N, Maier D, Merlo A, Tada M,
Sawamura Y, Diserens AC and Van Meir EG: Frequent co-alterations of
TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human
glioma cell lines. Brain Pathol. 9:469–479. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Poulaki V, Mitsiades CS, McMullan C,
Sykoutri D, Fanourakis G, Kotoula V, Tseleni-Balafouta S, Koutras
DA and Mitsiades N: Regulation of vascular endothelial growth
factor expression by insulin-like growth factor I in thyroid
carcinomas. J Clin Endocrinol Metab. 88:5392–5398. 2003. View Article : Google Scholar : PubMed/NCBI
|
